EZH2: a novel target for cancer treatment

被引：579

作者：

Duan, Ran ^{[1
,2
]}

Du, Wenfang ^{[3
]}

Guo, Weijian ^{[1
,2
]}

机构：

[1] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China

[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China

[3] Fudan Univ, Shanghai Med Coll, Shanghai 200032, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2020年 / 13卷 / 01期

关键词：

EZH2; Cancer; inhibitor; HOMOLOG; 2; EZH2; EPITHELIAL-MESENCHYMAL TRANSITION; GROUP PROTEIN EZH2; SELECTIVE-INHIBITION; HISTONE METHYLTRANSFERASE; BREAST-CANCER; POLYCOMB; METHYLATION; CELLS; PROSTATE;

D O I：

10.1186/s13045-020-00937-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Enhancer of zeste homolog 2 (EZH2) is enzymatic catalytic subunit of polycomb repressive complex 2 (PRC2) that can alter downstream target genes expression by trimethylation of Lys-27 in histone 3 (H3K27me3). EZH2 could also regulate gene expression in ways besides H3K27me3. Functions of EZH2 in cells proliferation, apoptosis, and senescence have been identified. Its important roles in the pathophysiology of cancer are now widely concerned. Therefore, targeting EZH2 for cancer therapy is a hot research topic now and different types of EZH2 inhibitors have been developed. In this review, we summarize the structure and action modes of EZH2, focusing on up-to-date findings regarding the role of EZH2 in cancer initiation, progression, metastasis, metabolism, drug resistance, and immunity regulation. Furtherly, we highlight the advance of targeting EZH2 therapies in experiments and clinical studies.

引用

页数：12

共 99 条

[41] The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer
Li, Zhongwei
Hou, Pingfu
Fan, Dongmei
Dong, Meichen
Ma, Musong
Li, Hongyuan
Yao, Ruosi
Li, Yuxin
Wang, Guannan
Geng, Pengyu
Mihretab, Adhanom
Liu, Dongxu
Zhang, Yu
Huang, Baiqu
Lu, Jun
[J]. CELL DEATH AND DIFFERENTIATION, 2017, 24 (01) : 59 - 71
[42] LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC
Liu, Xinyin
Lu, Xiyi
Zhen, Fuxi
Jin, Shidai
Yu, Tongfu
Zhu, Quan
Wang, Wei
Xu, Kun
Yao, Jiaqi
Guo, Renhua
[J]. MOLECULAR THERAPY-NUCLEIC ACIDS, 2019, 16 : 155 - 161
[43] Regulation of Tumor Angiogenesis by EZH2
Lu, Chunhua
Han, Hee Dong
Mangala, Lingegowda S.
Ali-Fehmi, Rouba
Newton, Christopher S.
Ozbun, Laurent
Armaiz-Pena, Guillermo N.
Hu, Wei
Stone, Rebecca L.
Munkarah, Adnan
Ravoori, Murali K.
Shahzad, Mian M. K.
Lee, Jeong-Won
Mora, Edna
Langley, Robert R.
Carroll, Amy R.
Matsuo, Koji
Spannuth, Whitney A.
Schmandt, Rosemarie
Jennings, Nicholas B.
Goodman, Blake W.
Jaffe, Robert B.
Nick, Alpa M.
Kim, Hye Sun
Guven, Eylem Ozturk
Chen, Ya-Huey
Li, Long-Yuan
Hsu, Ming-Chuan
Coleman, Robert L.
Calin, George A.
Denkbas, Emir B.
Lim, Jae Yun
Lee, Ju-Seog
Kundra, Vikas
Birrer, Michael J.
Hung, Mien-Chie
Lopez-Berestein, Gabriel
Sood, Anil K.
[J]. CANCER CELL, 2010, 18 (02) : 185 - 197
[44] SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer
Lu, W.
Liu, S.
Li, B.
Xie, Y.
Izban, M. G.
Ballard, B. R.
Sathyanarayana, S. A.
Adunyah, S. E.
Matusik, R. J.
Chen, Z.
[J]. ONCOGENE, 2017, 36 (10) : 1364 - 1373
[45] EZH2-Mediated microRNA-139-5p Regulates Epithelial-Mesenchymal Transition and Lymph Node Metastasis of Pancreatic Cancer
Ma, Jin
Zhang, Jun
Weng, Yuan-Chi
Wang, Jian-Cheng
[J]. MOLECULES AND CELLS, 2018, 41 (09) : 868 - 880
[46] EZH2 couples pancreatic regeneration to neoplastic progression
Mallen-St Clair, Jon
Soydaner-Azeloglu, Rengin
Lee, Kyoung Eun
Taylor, Laura
Livanos, Alexandra
Pylayeva-Gupta, Yuliya
Miller, George
Margueron, Raphael
Reinberg, Danny
Bar-Sagi, Dafna
[J]. GENES & DEVELOPMENT, 2012, 26 (05) : 439 - 444
[47] EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, Michael T.
Ott, Heidi M.
Ganji, Gopinath
Korenchuk, Susan
Thompson, Christine
Van Aller, Glenn S.
Liu, Yan
Graves, Alan P.
Della Pietra, Anthony, III
Diaz, Elsie
LaFrance, Louis V.
Mellinger, Mark
Duquenne, Celine
Tian, Xinrong
Kruger, Ryan G.
McHugh, Charles F.
Brandt, Martin
Miller, William H.
Dhanak, Dashyant
Verma, Sharad K.
Tummino, Peter J.
Creasy, Caretha L.
[J]. NATURE, 2012, 492 (7427) : 108 - +
[48] DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
Miranda, Tina Branscombe
Cortez, Connie C.
Yoo, Christine B.
Liang, Gangning
Abe, Masanobu
Kelly, Theresa K.
Marquez, Victor E.
Jones, Peter A.
[J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (06) : 1579 - 1588
[49] CBX7 regulates stem cell-like properties of gastric cancer cells via p16 and AKT-NF-κB-miR-21 pathways
Ni, Su-Jie
Zhao, Li-Qin
Wang, Xiao-Feng
Wu, Zhen-Hua
Hua, Rui-Xi
Wan, Chun-Hua
Zhang, Jie-Yun
Zhang, Xiao-Wei
Huang, Ming-Zhu
Gan, Lu
Sun, Hua-Lin
Dimri, Goberdhan P.
Guo, Wei-Jian
[J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[50] Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
Ntziachristos, Panagiotis
Tsirigos, Aristotelis
Van Vlierberghe, Pieter
Nedjic, Jelena
Trimarchi, Thomas
Flaherty, Maria Sol
Ferres-Marco, Dolors
da Ros, Vanina
Tang, Zuojian
Siegle, Jasmin
Asp, Patrik
Hadler, Michael
Rigo, Isaura
De Keersmaecker, Kim
Patel, Jay
Tien Huynh
Utro, Filippo
Poglio, Sandrine
Samon, Jeremy B.
Paietta, Elisabeth
Racevskis, Janis
Rowe, Jacob M.
Rabadan, Raul
Levine, Ross L.
Brown, Stuart
Pflumio, Francoise
Dominguez, Maria
Ferrando, Adolfo
Aifantis, Iannis
[J]. NATURE MEDICINE, 2012, 18 (02) : 298 - 303

← 1 2 3 4 5 6 7 8 9 10 →